

51. M/XDR treatment: toxicity and stigma
Sunday, 06 December 2015, 12:15-13:15

Chair: Martie VAN DER WALT (South Africa)

Track: Drug-resistant TB care and treatment, including trials

- PC-1132-06** **Adverse events among MDR-TB patients receiving second-line treatment in Cubal, Angola**
Ml Aznar, C Bocanegra, E Gabriel, A Zacarías, I Molina, R De Carvalho, M Moreno, T Lopez (*Spain, Angola*)
- PC-1133-06** **QTc interval in patient treated with a 9-month regimen for multidrug-resistant tuberculosis**
M-L- Mbulula-Mawagali, Z Kashongwe Munogolo, J Toloko, F Kassa, M Gninafon, W Bekou, A Trebucq, K G Koura (*Congo - Democratic Rep., Benin, France*)
- PC-1134-06** **Aminoglycoside ototoxicity in tuberculosis treatment: a review of the World Health Organization global pharmacovigilance database**
E Sagwa, P.c. Souverein, I Ribeiro, Hgm Leufkens, A Mantel-Teeuwisse (*Namibia*)
- PC-1135-06** **The effect of moxifloxacin and clofazimine on the corrected QT interval (QTc) in patients treated with a 9-month regimen for MDR-TB in Niger**
S Hassane Harouna, A Piubello, B Souleymane, S Morou, I Boukary, A Sala, K G Koura (*Niger, France*)
- PC-1136-06** **Hearing thresholds of drug-resistant tuberculosis patients: baseline audiogram configurations and associations**
M Fadeyi, A Sogebi, V Ibeziako, A Agbaje, E Usoroh, S Dutt, Patr Dakum (*Nigeria*)
- PC-1137-06** **Prevalence of depression and anxiety during treatment of MDR-TB patients in a tertiary care hospital**
Z Barry, Sara Khan, S Khan, O Qureshi, A Pasha, S Rehman, H Hussain, A Malik (*Pakistan*)
- PC-1138-06** **Occurrence of adverse events in patient receiving community-based therapy for multidrug-resistant tuberculosis in Pakistan**
Arsh Javaid, Ma Khan, S Mehreen, A Basit, Khan Afsarafridi, U Ullah, M Khan (*Pakistan*)
- PC-1139-06** **Adolescents' experiences of multidrug-resistant tuberculosis and of participation in clinical research**
K Zimri, P Rose, A Garcia-Prats, A Hesselning, H S Schaaf, G Hoddinott, L Viljoen (*South Africa*)
- PC-1140-06** **Improving pharmacovigilance of drug-resistant tuberculosis drugs**
N Misra, I Master (*South Africa*)